Mesoblast Ltd (ASX: MSB) Share Price and News

Dr. Itescu, prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. Itescu has consulted for international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.

Dr. Rose is a physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion. Former directorships of listed public companies within the last 3 years: Chairman, SIGA Technologies, Inc. (2017 - 2021), Non-executive Director, ABIOMED, Inc. which was acquired by Johnson & Johnson. (2007 - 2012, 2014 - 2022

Mr. Burns has served on the Board of Directors since 2014 and was appointed Vice Chairman in 2016. He spent his management career at the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp.

Ms. Bell AM has 30 years' experience as a banking and finance lawyer with leading law firms, financial services and corporate treasury operations in the United States, Canada, Australia and the United Kingdom. She is a Chair and non-executive Director in regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. She currently serves as Deputy Chair of Monash Health; she is also a director of publicly listed biotechnology company Amplia Therapeutics.

Mr Facchina has over forty years of experience in corporate strategy, finance, and business development across several industries, including healthcare.

Dr Krause has 30 years of experience at the Food and Drug Administration, he has a combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development.

Ms. Cobley has 30 years' executive experience in senior positions at Australian and Global banks with experience in P&L leadership, risk management, equity and debt capital markets, balance sheet management, strategy and leadership, people and culture matters, technology, cybersecurity and navigating complexity in regulated industries. She was previously CEO of Westpac Institutional Bank, Chair of Westpac Asia Advisory Board.

Dr. George is the founding principal of SurgCenter Development, privately owned ambulatory surgical center (ASC) company in the United States. As an Ophthalmologist with a very busy practice and high surgical volume, he recognized the necessity for surgeons to have more control over their daily schedule, surgical time, operating room protocols, and surgical staffing.

-

-

-

-

-

-

-

-

-

-

-

-